1. Home
  2. FC vs EDIT Comparison

FC vs EDIT Comparison

Compare FC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Covey Company

FC

Franklin Covey Company

HOLD

Current Price

$19.95

Market Cap

193.2M

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.09

Market Cap

202.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FC
EDIT
Founded
1983
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
193.2M
202.1M
IPO Year
1992
2016

Fundamental Metrics

Financial Performance
Metric
FC
EDIT
Price
$19.95
$2.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$26.00
$4.50
AVG Volume (30 Days)
151.4K
2.0M
Earning Date
01-07-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$262,026,000.00
$46,383,000.00
Revenue This Year
$3.22
N/A
Revenue Next Year
$2.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.04
$0.91
52 Week High
$39.22
$4.54

Technical Indicators

Market Signals
Indicator
FC
EDIT
Relative Strength Index (RSI) 60.70 45.17
Support Level $19.79 $2.05
Resistance Level $21.46 $2.43
Average True Range (ATR) 1.03 0.15
MACD 0.04 0.02
Stochastic Oscillator 72.99 31.47

Price Performance

Historical Comparison
FC
EDIT

About FC Franklin Covey Company

Franklin Covey Co is a company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education division, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the Australia, New Zealand, China, Japan, United Kingdom, Ireland, and Other countries.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: